Prognostic factors in 1038 women with metastatic breast cancer

R. Largillier, Jean-­Marc Ferrero, J. Doyen, +12

Annals of Oncology

Metastatic Breast CancerBreast OncologyMedicineBreast CancerOncology +1

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer

P. Fumoleau, R. Largillier, Christine Clippe, +12

European Journal of Cancer

Breast OncologyOncologyMedicinePhase Ii StudyBreast Cancer +4

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

Anthony Gonçalvès, Marine Gilabert, E. François, +16

Annals of Oncology

Pancreatic CancerGastrointestinal OncologyMedicineClinical TrialsDouble-blind Phase Iii +7

Imaging in Evaluation of Response to Neoadjuvant Breast Cancer Treatment Benefits of MRI

C. Balu–Maestro, C. Chapellier, A. Bleuse, +3

Breast Cancer Research and Treatment

EngineeringOncologic ImagingMedical ImagingBiomedical ImagingBreast Imaging +8

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

Uwe Wagner, Christian Marth, R. Largillier, +8

British Journal of Cancer

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly, +61

The Lancet Oncology

Carboplatin-based DoubletMedicineMetronomic TherapyGynecologyPlatinum-sensitive Ovarian Cancer +5

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group

Patricia Pautier, Anne Floquet, Laurence Gladieff, +20

Annals of Oncology

Localized Uterine SarcomasMedicineCancer ManagementAdjuvant ChemotherapyGynecology +6

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled, +342

The Lancet

Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer +4

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity

S. Beauclair, Patricia Formento, Jean–Louis Fischel, +7

Annals of Oncology

Trastuzumab-related CardiotoxicityPathologyImmune-related Gene PolymorphismBreast CancerCancer Genetics +4

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO)

Alain Lortholary, R. Largillier, B. Weber, +7

Annals of Oncology

Resistant Ovarian CancerOncologyWeekly TopotecanMedicineGynecology +7